Cited by 201Antifungal resistance and susceptibilityFungal Plant Pathogen ControlYeasts and Rust Fungi Studies

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Amphotericin B and Caspofungin Resistance in Candida glabrata Isolates Recovered from a Critically Ill Patient

Krogh-Madsen, M., Arendrup, M. C., Heslet, L., Knudsen, J. D.·2006·Clinical Infectious Diseases

Open this paper in CoChat — free account

Abstract

BACKGROUND: Consecutive Candida glabrata isolates recovered from a patient in an intensive care unit were resistant to amphotericin B (minimum inhibitory concentration, up to 32 mu g/mL; determined by Etest [AB Biodisk]). Analyses at the national reference laboratory showed that some isolates were also resistant to azoles and caspofungin. In this study, 4 isolates were studied thoroughly using susceptibility assays and a mouse model and to determine clonality. METHODS: Different broth microdilution tests, Etests, and time-kill studies for antifungals were performed in different media. Three of the 4 isolates were examined in an in vivo experiment, in which mice were challenged intravenously with 1 of 3 isolates and treated daily with amphotericin B, caspofungin, or saline. For the clonality studies, arbitrarily primed polymerase chain reaction (PCR) was performed with the 4 isolates, 8 isolates obtained from nonrelated patients, and a reference strain. RESULTS: The murine model indicated that 1 isolate was resistant to amphotericin B, 1 had intermediate susceptibility, and 1 was fully susceptible. Two of the 3 isolates were resistant to caspofungin. Microdilution methods did not reliably differentiate between amphotericin B-susceptible and -resistant isolates. All assays identified caspofungin-susceptible and -resistant isolates. Arbitrarily primed PCR showed that the 4 isolates probably were of clonal origin. CONCLUSIONS: We have documented the emergence of amphotericin B-resistant and caspofungin-resistant C. glabrata isolates during treatment of a critically ill liver transplant recipient. Only the Etest predicted amphotericin B resistance in the isolates. We recommend that important fungal strains recovered from patients who are receiving antifungal therapy should be tested for susceptibility to the antifungal drug used, because resistance can be present initially or may occur during treatment.

Integrity signals

Registry

Crossref · 10.1086/500939

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Amphotericin B: spectrum and resistance
Ellis, D. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.suppl_1.7 · Cited by 474
Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000
Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., & Hollis, R. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.852-856.2002 · Cited by 331
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors
OXFORD, J. S., Bossuyt, S., Balasingam, S., Mann, A., Novelli, P., & Lambkin‐Williams, R. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00564.x · Cited by 231
Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts
Rodríguez-Tudela, J. L., Barchiesi, F., Billé, J., Chryssanthou, E., Cuenca‐Estrella, M., Denning, D. W., Donnelly, J. P., Dupont, B., Fegeler, W., Moore, C. B., et al. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00789.x · Cited by 208
Detection of amphotericin B-resistant Candida isolates in a broth-based system
Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.906 · Cited by 198
Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002
Pfaller, M. A., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3142-3146.2004 · Cited by 183
Seminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility
Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Jensen, I. M., Knudsen, J. D., Lundgren, B., Schønheyder, H. C., & Tvede, M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4434-4440.2005 · Cited by 177
Self-citation
In Vivo Pathogenicity of Eight Medically Relevant Candida Species in an Animal Model
Arendrup, M. C., Horn, T. D., & Møller, J. K. (2002) · Infection · doi:10.1007/s15010-002-2131-0 · Cited by 169
Self-citation
Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis
Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.4.1382-1383.2004 · Cited by 162
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome
Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 138

Flagged first, then by citations

Show all 21 references

Sorted by citations

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins
Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445
Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
Antifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008
Pfaller, M. A., Neofytos, D., Diekema, D. J., Azie, N. E., Meier‐Kriesche, H., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 391
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 391
Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250
Candida Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009
Pfaller, M. A., Moet, G. J., Messer, S. A., Jones, R. N., & Castanheira, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01079-10 · Cited by 238
Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens
Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226
Invasive Candidiasis
Pappas, P. G. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.004 · Cited by 233
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme
Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206
Self-citation
The Echinocandins
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196
Systematic Phenotyping of a Large-Scale Candida glabrata Deletion Collection Reveals Novel Antifungal Tolerance Genes
Schwarzmüller, T., Ma, B., Hiller, E., Istel, F., Tscherner, M., Brunke, S., Ames, L., Firon, A., Green, B., Cabral, V., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004211 · Cited by 191
Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility
Katiyar, S. K., Pfaller, M. A., & Edlind, T. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009)
Pfaller, M. A., Castanheira, M., Messer, S. A., Moet, G. J., & Jones, R. N. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.06.015 · Cited by 180
Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
Gonçalves, S. S., Souza, A. C. R., Chowdhary, A., Meis, J. F. G. M., & Colombo, A. L. (2016) · Mycoses · doi:10.1111/myc.12469 · Cited by 186
Current challenges in the management of invasive fungal infections
Lai, C., Tan, C., Huang, Y., Shao, P., & Hsueh, P. (2008) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-007-0595-7 · Cited by 167
Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases
Nami, S., Aghebati‐Maleki, A., Morovati, H., & Maleki, L. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.009 · Cited by 169
Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults
Sandison, T., Ong, V., Lee, J., & Thye, D. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01627-16 · Cited by 161
Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 159
Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140
Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Caspofungin Susceptibility Testing of Candida and Aspergillus Species
Carolis, E. D., Vella, A., Florio, A. R., Posteraro, P., Perlin, D. S., Sanguinetti, M., & Posteraro, B. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00224-12 · Cited by 140
FKS Mutations and Elevated Echinocandin MIC Values among Candida glabrata Isolates from U.S. Population-Based Surveillance
Zimbeck, A. J., Iqbal, N., Ahlquist, A. M., Farley, M. M., Harrison, L. H., Chiller, T., & Lockhart, S. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00836-10 · Cited by 136
Mecanismos de resistencia a los antifúngicos: levaduras y hongos filamentosos
Espinel‐Ingroff, A. (2008) · Revista Iberoamericana de Micología · doi:10.1016/s1130-1406(08)70027-5 · Cited by 141
In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model
Andes, D. R., Diekema, D. J., Pfaller, M. A., Marchillo, K., & Bohrmueller, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00478-08 · Cited by 134
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
Maubon, D., Garnaud, C., Calandra, T., Sanglard, D., & Cornet, M. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3404-7 · Cited by 141
Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing
Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
A review of Candida species causing blood stream infection
Giri, S., & Kindo, A. J. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.99484 · Cited by 132
Recent advances in antifungal chemotherapy
Petrikkos, G. L., & Skiada, A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.03.009 · Cited by 127
Recent advances and challenges in the treatment of invasive fungal infections
Shao, P., Huang, L., & Hsueh, P. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.07.019 · Cited by 131
Antifungal drug resistance mechanisms
Pemán, J., Cantón, E., & Espinel‐Ingroff, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.18 · Cited by 121
Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
Andes, D. R., Ambrose, P. G., Hammel, J., Wart, S. A. V., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119
Reduced Candida glabrata Susceptibility Secondary to an FKS1 Mutation Developed during Candidemia Treatment
Cleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-07 · Cited by 118
Differential In Vivo Activities of Anidulafungin, Caspofungin, and Micafungin against Candida glabrata Isolates with and without FKS Resistance Mutations
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117
Self-citation
Current status of antifungal resistance and its impact on clinical practice
Alcázar‐Fuoli, L., & Mellado, E. (2014) · British Journal of Haematology · doi:10.1111/bjh.12896 · Cited by 118
Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment
Guery, B. P., Arendrup, M. C., Auzinger, G. M., Azoulay, É., Borges-Sa, M., Johnson, E. M., Müller, E. E., Putensen, C., Rotstein, C., Sganga, G., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1339-6 · Cited by 116
Self-citation
Establishing In Vitro-In Vivo Correlations for Aspergillus fumigatus : the Challenge of Azoles versus Echinocandins
Arendrup, M. C., Perkhofer, S., Howard, S. J., García‐Effrón, G., Aimanianda, V., Perlin, D. S., & Lass‐Flörl, C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00190-08 · Cited by 115
Self-citation
Facultative Sterol Uptake in an Ergosterol-Deficient Clinical Isolate of Candida glabrata Harboring a Missense Mutation in ERG11 and Exhibiting Cross-Resistance to Azoles and Amphotericin B
Hull, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06253-11 · Cited by 113
Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches
Beyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109
The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0016-6 · Cited by 104
Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient
Chapeland‐Leclerc, F., Hennequin, C., Papon, N., Noël, T., Girard, A., Socié, G., Ribaud, P., & Lacroix, C. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01138-09 · Cited by 104
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 108
Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
Lewis, R. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89
Epidemiology and antifungal resistance in invasive candidiasis
Rodloff, A., Koch, D., & Schaumann, R. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-187 · Cited by 90
ERG6 and ERG2 Are Major Targets Conferring Reduced Susceptibility to Amphotericin B in Clinical Candida glabrata Isolates in Kuwait
Ahmad, S., Joseph, L., Parker, J. E., Asadzadeh, M., Kelly, S. L., Meis, J. F. G. M., & Khan, Z. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01900-18 · Cited by 85
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
Chimenti, F., Bizzarri, B., Maccioni, E., Secci, D., Bolasco, A., Fioravanti, R., Chimenti, P., Granese, A., Carradori, S., Rivanera, D., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.078 · Cited by 82
Epidemiology, Incidence and Risk Factors for Invasive Candidiasis in High-Risk Patients
Concia, E., Azzini, A. M., & Conti, M. (2009) · Drugs · doi:10.2165/11315500-000000000-00000 · Cited by 77
Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. – Trends over 10 years
Bailly, S., Maubon, D., Fournier, P., Pelloux, H., Schwebel, C., Chapuis, C., Foroni, L., Cornet, M., & Timsit, J. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.09.041 · Cited by 81
Antifungal Susceptibility Testing: A Primer for Clinicians
Wiederhold, N. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab444 · Cited by 81
In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Molina, D. K., Olivo, M., & Graybill, J. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-07 · Cited by 74
European expert opinion on the management of invasive candidiasis in adults
Kullberg, B. J., Verweij, P. E., Akova, M., Arendrup, M. C., Billé, J., Calandra, T., Cuenca‐Estrella, M., Herbrecht, R., Jacobs, F., Kalin, M., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03615.x · Cited by 72
Self-citation
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
Bow, E. J., Evans, G. A., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R. P., Shafran, S. D., Sheppard, D. C., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 70
Synthesis and antimicrobial activity of some new hydrazone-bridged thiazole-pyrrole derivatives
Yurttaş, L., Özkay, Y., Kaplancıklı, Z. A., Tunalı, Y., & Karaca, H. (2012) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.688043 · Cited by 69
Candidemia epidemiology and susceptibility profile in the largest Brazilian teaching hospital complex
Motta, A. L., de Almeida, G. M. D., de Almeida, J. N., Burattini, M. N., & Rossi, F. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70091-x · Cited by 69
Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin
Pfaller, M. A., Chaturvedi, V. P., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., & Ramani, R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00493-08 · Cited by 68
Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection
Vázquez, J. A., Skiest, D. J., Tissot‐Dupont, H., Lennox, J. L., Boparai, N., & Isaacs, R. (2007) · HIV Clinical Trials · doi:10.1310/hct0802-86 · Cited by 66
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 66
Echinocandin pharmacodynamics: review and clinical implications
Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 71
Tipping the balance both ways: drug resistance and virulence in Candida glabrata
Vale-Silva, L. A., & Sanglard, D. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov025 · Cited by 71
Clinical efficacy of new antifungal agents
Kauffman, C. A. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.001 · Cited by 64
Potential inhibitory activity of phytoconstituents against black fungus: In silico ADMET, molecular docking and MD simulation studies
Hussen, N. H., Hasan, A. H., Jamalis, J., Shakya, S., Chander, S., Kharkwal, H., Murugesan, S., Bastikar, V. A., & Gupta, P. P. (2022) · Computational Toxicology · doi:10.1016/j.comtox.2022.100247 · Cited by 64
The value of amphotericin B in the treatment of invasive fungal infections
Klepser, M. E. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.08.005 · Cited by 64
Detection of Amphotericin B Resistance in Candida haemulonii and Closely Related Species by Use of the Etest, Vitek-2 Yeast Susceptibility System, and CLSI and EUCAST Broth Microdilution Methods
Shin, J. H., Kim, M., Jang, S. J., Ju, M. Y., Kim, S. H., Shin, M., Suh, S., & Ryang, D. W. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06440-11 · Cited by 61
Epidemiology and Antifungal Susceptibility of Bloodstream Candida Isolates in Quebec: Report on 453 Cases between 2003 and 2005
St‐Germain, G., Laverdière, M., Pelletier, R., René, P., Bourgault, A., Lemieux, C., & Libman, M. (2007) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/634046 · Cited by 62
Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 61
Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02120-10 · Cited by 59
The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety
Wiederhold, N. P., & Lewis, J. S. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1155 · Cited by 57
Recent insights into the mechanisms of antifungal resistance
Barker, K. S., & Rogers, P. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0019-3 · Cited by 54
Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection
Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 54
Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans
Wiederhold, N. P., Grabinski, J. L., García‐Effrón, G., Perlin, D. S., & Lee, S. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00959-08 · Cited by 51
Editorial Commentary: Candida glabrata and FKS Mutations: Witnessing the Emergence of the True Multidrug-Resistant Candida
Ostrosky‐Zeichner, L. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit140 · Cited by 51
Pharmacokinetics and Pharmacodynamics of Antifungals in Children and their Clinical Implications
Stockmann, C. R., Constance, J. E., Roberts, J. K., Olson, J. A., Doby, E. H., Ampofo, K., Stiers, J., Spigarelli, M. G., & Sherwin, C. M. T. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0139-0 · Cited by 51
Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?
Soulountsi, V., Schizodimos, T., & Kotoulas, S. (2021) · Infection · doi:10.1007/s15010-021-01640-7 · Cited by 52
A comparative evaluation of properties and clinical efficacy of the echinocandins
Kim, R., Khachikian, D., & Reboli, A. C. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.10.1479 · Cited by 49
Interactions between Candida albicans and Candida glabrata in biofilms: Influence of the strain type, culture medium and glucose supplementation
Hosida, T. Y., Cavazana, T. P., Henriques, M., Pessan, J. P., Delbem, A. C. B., & Monteiro, D. R. (2017) · Mycoses · doi:10.1111/myc.12738 · Cited by 57
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.
Jensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47
Self-citation
Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.
Rodrigues, C. F., & Henriques, M. (2017) · Pathogens · doi:10.3390/pathogens6040062 · Cited by 48
Comparison of antifungal MICs for yeasts obtained using the EU-CAST method in a reference laboratory and the Etest in nine different hospital laboratories
Dannaoui, É., Paugam, A., Develoux, M., Chochillon, C., Matheron, J., Datry, A., Bouges‐Michel, C., Bonnal, C., Dromer, F., & Bretagne, S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02997.x · Cited by 45
Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via In Vivo Pharmacodynamic Evaluation against Candida glabrata with and without fks Mutations
Lepak, A. J., Castanheira, M., Diekema, D. J., Pfaller, M. A., & Andes, D. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-12 · Cited by 42
In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan
Yamazaki, T., Inagaki, Y., Fujii, T., Ohwada, J., Tsukazaki, M., UMEDA, I., Kobayashi, K., Shimma, N., Page, M. G. P., & Arisawa, M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.003 · Cited by 40
In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility
Cota, J. M., Carden, M., Graybill, J. R., Najvar, L. K., Burgess, D. S., & Wiederhold, N. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00538-06 · Cited by 40
Juruin: an antifungal peptide from the venom of the Amazonian Pink Toe spider, Avicularia juruensis, which contains the inhibitory cystine knot motif
Ayroza, G., Candido-Ferreira, I., Sayegh, R. S. R., Tashima, A. K., & da Silva, P. I. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00324 · Cited by 39
In vitro activity of 23 tea extractions and epigallocatechin gallate against Candida species
Chen, M., Zhai, L., & Arendrup, M. C. (2015) · Medical Mycology · doi:10.1093/mmy/myu073 · Cited by 41
Self-citation
FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin Therapy
Costa‐de‐Oliveira, S., Miranda, I. M., Silva, R. M., Silva, A. P., Rocha, R., Amorim, A., Rodrigues, A. G., & Pina‐Vaz, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00589-10 · Cited by 37
Candiduria; a review article with specific data from Iran
Taghipour, S., Mahmoudabadi, A. Z., Gharaghani, M., & Halvaeezadeh, M. (2018) · Urology Research and Practice · doi:10.5152/tud.2018.54069 · Cited by 37
Detection of Caspofungin Resistance in Candida spp. by Etest
Desnos‐Ollivier, M., Dromer, F., & Dannaoui, É. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00053-08 · Cited by 35
Interactions of Yeasts, Moulds, and Antifungal Agents
Hall, G. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5 · Cited by 33
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch29 · Cited by 33
Antifungal Susceptibility of Bloodstream Candida Isolates in Sfax Hospital: Tunisia
Sellami, A., Sellami, H., Néji, S., Makni, F., Abbes, S., Cheikhrouhou, F., Chelly, H., Bouaziz, M., Hammami, B., Jemâa, M. B., et al. (2010) · Mycopathologia · doi:10.1007/s11046-010-9388-0 · Cited by 32

Authors: Krogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D.
Affiliations: Hvidovre Hospital (DK)
Statens Serum Institut (DK)
Corresponding author: Knudsen, J. D.
ORCID: Arendrup, M. C.
Knudsen, J. D.
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2006-04-01
Volume: 42
Issue: 7
Pages: 938-944
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1086/500939
OpenAlex: W2106522725
Cited by: 201
References: 21
Citations by year: 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 3 · 2021: 11 · 2020: 3 · 2019: 4 · 2018: 6 · 2017: 5 · 2016: 14 · 2015: 9 · 2014: 15 · 2013: 6 · 2012: 20
FWCI: 13.56
Type: journal article
Language: en
Open access: closed
Locations: Clinical Infectious Diseases (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
Keywords: Candida glabrata, amphotericin B resistance, caspofungin resistance, antifungal resistance, critically ill patients, liver transplant recipients, clonality, E-test, antifungal susceptibility testing, time-kill assay, mouse model, azole resistance
MeSH terms: Caspofungin, Aged, Amphotericin B, Animals, Antifungal Agents, Candidiasis, Female, Humans, Microbial Sensitivity Tests, Peptides, Cyclic, Polymerase Chain Reaction, Critical Illness, Candida glabrata, Mice, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Amphotericin B and Caspofungin Resistance in Candida glabrata Isolates Recovered from a Critically Ill Patient

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks